📰 Advanced Accelerator News
Advanced Accelerator News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Accelerator. Real-time updates on events, politics, business and more.
April 23, 2024
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
January 26, 2024
By Adriano Marchese Lantheus Holdings is being sued by Swiss multinational pharmaceutical Novartis for patent infringement on a generic drug to treat...
January 20, 2024
Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.
July 19, 2023
Neuroendocrine Carcinoma Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The
February 3, 2023
NOIDA, India, Feb. 3, 2023 /PRNewswire/ -- According to a new report published by UnivDatos Markets Insights, the Neuroendocrine Tumor Treatment Market was valued at more than USD 1500
February 3, 2023
/PRNewswire/ -- According to a new report published by UnivDatos Markets Insights, the Neuroendocrine Tumor Treatment Market was valued at more than USD 1500...
October 11, 2022
Investigators addressed the "holy grail" in thyroid oncology: how to jump-start radioactive iodine when it stops working for patients with thyroid cancer.
August 8, 2022
08.08.2022 - Brings 30 Years of Experience as a Former Endocyte and Novartis Regulatory ExecutiveDURHAM, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) - Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully ...
August 8, 2022
Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory AffairsBrings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive - read this article along with other careers information, tips and advice on BioSpace